Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases

 

Latest CSL News

Latest CSL News

CSL’s Global Role in Battling COVID-19
02 Apr 2021

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

COVID-19 Update
02 Apr 2021

CSL continues to provide medicines to patients around the world.

Local Manufacturing of COVID-19 Vaccine Update
12 Feb 2021

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).

AUS Clinical Trial of Treatment for COVID19
31 Jan 2021

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin

University of Oxford/AstraZeneca Vaccine Candidate
08 Nov 2020

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.

CSL Named as One of the World’s Best Employers
29 Oct 2020

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

Joy Linton named as Chief Financial Officer
01 Oct 2020

CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group.

CSL Media Statement on COVID19 Vaccine Manufacture
18 Aug 2020

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

Inaccurate Report of COVID-19 Vaccine Agreement
18 Jul 2020

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.

Rare Diseases in Asia-Pacific
16 Jul 2020

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.

Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.

Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.

UQ COVID 19 Vaccine to Commence Human Trials
13 Jul 2020

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

News archive 2016 pdf
News archive 2015 pdf
News archive 2014 pdf
News archive 2013 pdf